

1 **Serum fibrinogen level and fibrinogen administration in**
2 **patients with traumatic brain injury: a systematic review**
3 **and meta-analysis protocol**

4
5 Joanne Igoli^{1,2,#}, Jeremiah Oluwatomi Itodo Daniel^{2,#}, Halleluyah Oludele², Adedoyin Esther
6 Alao², Idemudia Stephen Ogedegbe², Adewale Olaniyan², Michael Adeshola Adebayo²,
7 Damilola Matthew², Temidayo Elizabeth Oyepitan², Daniel Brabi², Olatomiwa Olukoya^{2,3},
8 Temidayo Osunronbi^{2,4}

- 9
10 1. Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, United
11 Kingdom
12 2. Neurosurgery Department, Surgery Interest Group of Africa, Lagos, Nigeria
13 3. National Hospital for Neurology and Neurosurgery, London, United Kingdom
14 4. Department of Neurosurgery, Salford Royal NHS Foundation Trust, Manchester,
15 United Kingdom

16 # Joint-first authors: contributed equally.

17

18 **Please address all correspondence to:**

19

20 Dr Joanne Igoli

21 Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, United Kingdom.

22 EH16 4SB

23 Email: s1408071@sms.ed.ac.uk

24 ABSTRACT

25 **Introduction:** Traumatic Brain Injury (TBI) is a leading cause of disability and death
26 globally. It has a significant economic burden. Coagulopathy has been identified as one of
27 the key factors contributing to the poor outcomes observed in TBI patients, and it has been
28 theorised that the management of coagulopathy will improve patient outcomes.

29 Low serum fibrinogen levels denote a coagulopathic state, and the therapeutic
30 administration of fibrinogen has been proposed to correct this state. However, there is no
31 consensus on its efficacy in patients with TBI.

32 This systematic review and meta-analysis seeks to ascertain the prognostic value of
33 serum fibrinogen levels in patients with TBI and assess the effect of fibrinogen
34 administration on these patients.

35

36 **Methods:** Using the Preferred Reporting Items for Systematic Review and Meta-Analysis
37 Protocols (PRISMA-P) guidelines, we will perform a comprehensive search of Scopus,
38 Medline, Embase and Cochrane Library to retrieve all original articles that investigate the
39 prognostic value of fibrinogen levels and/or the effect of fibrinogen administration in TBI
40 patients. Primary outcomes include functional outcome and mortality assessments such

41 as the Glasgow Outcome Score and modified Rankin Score. Secondary outcomes include
42 progressive intracranial haemorrhage/contusion and need for surgical intervention. Data
43 collected will encompass participant demographics, measured fibrinogen levels, dose of
44 fibrinogen administered and specified outcome measures.

45
46 Conclusion: Findings from this study on if fibrinogen level has prognostic value and if
47 fibrinogen administration improves patient outcomes, will help inform future TBI
48 management and shared decision-making. Thus, TBI patient outcomes can be optimised
49 accordingly.

50
51 PROSPERO Registration Number: CRD42024556497. Available from:

52 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024556497

53
54 Keywords: Traumatic Brain Injury; Fibrinogen; Coagulopathy; Glasgow Outcome Scale;
55 modified Rankin Score

56
57 Short Title: Fibrinogen in TBI systematic review protocol.

58 Introduction

59 Traumatic Brain Injury (TBI) is a leading cause of disability and death, with an incidence of
60 approximately 69 million people per year globally[1] and a prevalence of approximately 75
61 million [1,2]. The estimated global economic cost of TBI is \$400 billion [3]. Approximately
62 half of TBI patients seen in hospitals fail to regain pre-TBI baseline health six months after
63 the injury [2]. Sequelae of TBI range from transient loss of consciousness and confusion to
64 seizures, persistent cognitive decline, coma, and death [4–6].

65
66 Coagulopathy in TBI influences the development of intracranial haemorrhage (ICH), leading
67 to poor patient outcomes, including a higher incidence of organ failure, poor neurological
68 function recovery, significant disability, and death [7–9]. Fibrinogen plays a vital role in the
69 clotting cascade of stabilising blood clots. A low fibrinogen level is a marker of
70 coagulopathy. Serum fibrinogen level has been shown to decrease significantly hours after
71 trauma and reaches severely low levels in uncontrolled post-traumatic bleed[10].
72 Furthermore, adverse associations of low fibrinogen levels in patients with TBI have been
73 shown, such as loss of independence due to severe disability, vegetative state, and death
74 [9,11,12]. It has been postulated that low fibrinogen levels can be used to prognosticate
75 patients with TBI, and therapeutic administration of fibrinogen could improve coagulopathy
76 in these patients, improving their outcomes.

77
78 This systematic review aims first to assess the evidence on the prognostic value of
79 fibrinogen in TBI, which would benefit risk-benefit shared decision-making involving

80 healthcare providers, patients, and their families. Secondly, the authors aim to evaluate the
81 evidence on the benefits, if any, of fibrinogen administration in patients with TBI, which, if
82 demonstrated, would transform and broaden treatment options in this group of patients.

83

84 Materials and Methods

85 Research Questions

86 **Question 1: Is there a prognostic value of fibrinogen level in patients with traumatic brain**
87 **injury?**

88

89 *Population:* Patients with traumatic brain injury (TBI)

90

91 *Intervention:* Serum fibrinogen level

92

93 *Control:* N/A

94

95 *Outcomes:* Glasgow outcome score; need for surgical intervention; mortality;

96 functional outcomes; progressive intracranial haemorrhage/contusion; other.

97

98

99

100 **Question 2: What is the effect of fibrinogen administration on outcomes in patients with**
101 **traumatic brain injury?**

102

103 *Population:* Patients with traumatic brain injury (TBI)

104

105 *Intervention:* Fibrinogen administered

106

107 *Control:* Fibrinogen not administered

108

109 *Outcomes:* Glasgow outcome score; need for surgical intervention; mortality;

110 functional outcomes; progressive intracranial haemorrhage/contusion; other.

111

112 Data Collection

113 Literature Search Strategy

114 We searched the abstracts and titles of articles in Medline, SCOPUS, Cochrane, and EMBASE

115 databases from inception to June 01, 2024, using the following search strategy:

116

117 #1 head OR craniu* OR crania* OR cerebra* OR cerebru* OR brain* OR forebrain* OR skull* OR

118 hemispher* OR intracran* OR intracerebral

119 #2 injur* OR trauma* OR damag* OR wound* OR fracture* OR contusion* OR haematoma OR

120 hematoma OR haemorrhage OR hemorrhage

121 #3 Factor I OR Fibrinogen OR Fibrin OR Fibrinogen concentrate OR Hypofibrinogenemia OR

122 Hypofibrinogenaemia OR Fibrin degradation product OR Coagulopathy OR Clot* OR Haematolog*

123 OR Hematolog* OR Cryoprecipitate OR Riastap OR Fresh Frozen Plasma

124 #4 #1 AND #2 AND #3

125

126 The initial results of the search strategy are shown in Table 1.

127 **Table 1: Search Strategy Table**

Database	Count
Scopus	38,066
Medline	8256
Embase	15139
Cochrane	2543

128

129 Eligibility Criteria

130 Inclusion Criteria

131 We will include full-text original articles that investigate the prognostic value of serum fibrinogen

132 level and/or investigate the effects of fibrinogen administration on outcomes in TBI patients.

133 Exclusion Criteria

134 Review articles, expert opinions, editorials, letters, conference abstracts, case reports, case series,

135 non-English language papers, paediatric-focussed studies and non-human studies will be excluded.

136 Studies in which fibrinogen was used solely as a marker of disease severity and/or solely for

137 diagnostic reasons will also be excluded.

138

139

140 Data Extraction

141 Zotero (Corporation for Digital Scholarship, Virginia, USA) will be used to exclude literature search
142 duplicates. Using Rayyan (Rayyan, Cambridge, Massachusetts, USA), titles/abstracts will be
143 independently screened by two reviewers for inclusion. Eligible full-text articles will be screened
144 further, and subsequent data extracted using the same data extraction proforma on Google Sheets
145 (Google LLC, Mountain View, California, USA). A third reviewer will adjudicate any conflicts in
146 title/abstract screening, full-text screening, and data extraction. The process will be illustrated using
147 a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [13] flow
148 diagram.

149

150 Data to be extracted:

- 151 ● Title
- 152 ● Author
- 153 ● Publication year
- 154 ● Study design
- 155 ● Country of study: Based on where the study took place. The first author's country will be
156 used when the study location is not specified.
- 157 ● Cause of TBI, if included, such as blunt trauma, penetrating trauma, other
- 158 ● Neurosurgical procedures carried out such as decompressive craniectomy or craniotomy
159 for extradural clot evacuation.

- 160 ● Exclusion criteria
- 161 ● Number of patients
- 162 ● Age (mean \pm SD/median (IQR))
- 163 ● Sex (male/female proportion)
- 164 ● Day serum fibrinogen blood sample was obtained
- 165 ● Average fibrinogen level
- 166 ● Level of serum fibrinogen that triggered fibrinogen administration (if serum fibrinogen was
- 167 checked pre-fibrinogen administration)
- 168 ● Day fibrinogen was administered: Preoperative or postoperative. If postoperative, the day(s)
- 169 fibrinogen was administered will be extracted
- 170 ● Dose(s) of fibrinogen administered
- 171 ● Number of times fibrinogen was administered and the triggers for subsequent
- 172 administration
- 173 ● Outcome measure: The nature of the outcome measure to be identified is uncertain.
- 174 Therefore, there will be no prior criteria. It is anticipated that outcomes such as the
- 175 following will be identified and used as inclusion criteria:
 - 176 ○ Glasgow Outcome Score (GOS)/Glasgow Outcome Score Extended (GOSE)
 - 177 ○ Modified Rankin Score
 - 178 ○ Mortality
 - 179 ○ Quality of life
 - 180 ○ Progressive intracranial haemorrhage/contusion
 - 181 ○ Other
- 182 For each outcome measure, the following will be extracted:
 - 183 ○ Length of stay (LOS)
 - 184 ○ Number of patients with event/number without event

- 185 ○ Length of follow-up
- 186 ○ Number of patients lost to follow-up
- 187 ○ Low serum fibrinogen threshold
- 188 ○ The method used for threshold selection
- 189 ○ Area under the curve (AUC)
- 190 ○ Sensitivity
- 191 ○ Specificity
- 192 ○ Event ratio with 95% confidence interval (CI)
- 193 ○ Conclusion (on the association between fibrinogen level and outcome measure; on
- 194 association between fibrinogen administration and outcome measure).
- 195 Multivariate data will be preferred if both multivariate and univariate data are provided.
- 196 However, univariate data will be used instead in the absence of multivariate data. For AUC,
- 197 solely univariate data will be used.

198

199 **Data Analysis**

200 The direction of effect for the association between serum fibrinogen level or fibrinogen
201 administration and patient outcomes will be categorised as significantly positive, significantly
202 negative, or not statistically significant from articles where the event ratio is reported. Where the
203 area under the curve (AUC) is reported, the effect direction will be grouped as failed (AUC = 0.5 to
204 0.6), poor (AUC = 0.6 to 0.7), acceptable (AUC = 0.7 to 0.8), good (AUC = 0.8 to 0.9) and excellent
205 (AUC > 0.9) [14]. Dose and response analyses will be done [15], where possible, to evaluate the most
206 effective dose of fibrinogen administration. Side effect frequency and severity will be reported.
207

208 Where possible, if ≥ 5 appropriate articles, meta-analysis will be performed using Review Manager
209 (RevMan) (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration) as follows:
210 each outcome measure will have a pooled extracted odds ratio (OR)/hazard ratio (HR) with the
211 corresponding 95% confidence interval (CI). The generic inverse-variance method will be used to
212 assess the association between fibrinogen level/fibrinogen administration and the dichotomous
213 outcome measure. The Cochrane Q-statistic and I^2 statistic tests will be used to assess
214 heterogeneity among included studies. Study heterogeneity will be addressed using a random-
215 effects model. Subgroup analyses will be carried out for studies that explicitly state that their study
216 participants had isolated head injuries. Subgroup analyses will be conducted through sensitivity
217 analysis, where the primary analysis is repeated after excluding studies with a high risk of bias. The
218 risk of bias (RoB) in the eligible full-text articles will be assessed by two independent reviewers, with
219 a third reviewer adjudicating any discrepancies.

220
221 The RoB in studies investigating the prognostic utility of serum fibrinogen level will be assessed
222 using the Quality in prognosis studies (QUIPs) tool [16]. The categories of high, moderate, and low
223 risk of bias will used based on the criteria developed by Grooten et al [16]: green (low risk of bias) for
224 studies where all six QUIPs domains are assessed as low risk of bias (RoB) or not more than one
225 domain is assessed as moderate risk of bias; red (high RoB) for studies where ≥ 1 is assessed as
226 high RoB, or ≥ 3 domains are assessed as moderate RoB; yellow (moderate RoB) for all other
227 articles in between. The same criteria will be used to assess the risk of bias rating for individual
228 domains.

229
230 For the studies investigating the efficacy of fibrinogen administration, the Cochrane Risk of Bias
231 tool will be used for Randomised control trials (RCTs) [17], and the ROBINS-I tool for non-
232 randomised studies to determine the RoB [18]. The RoB of RCTs will be rated as high, low, or

233 unclear. A green circle with a '+' symbol within will be used for low RoB, a red circle with a '-' symbol
234 within for high RoB, and a yellow circle with a '?' symbol within for unclear RoB. For the ROBINS-I
235 tool the categories used will be low risk, moderate risk, serious risk, and critical risk of bias [18].
236 Publication bias will be assessed through funnel plots and Egger's regression test, contingent on
237 having an adequate number of studies. The GRADE framework will be used to assess the certainty
238 of the evidence of the synthesis findings for each outcome measure in cases of fibrinogen
239 administration and prognostication [19,20]. Two independent reviewers will conduct the GRADE
240 assessments, with a third reviewer adjudicating any discrepancies.
241
242 If meta-analysis is not possible, the Synthesis without meta-analysis (SWiM) in systematic review
243 reporting guidelines will be used to report narrative and qualitative data [21].

244 Study Limitations

245 Due to the nature of this systematic review's exclusion criteria, potentially valuable information in
246 these excluded studies may be missed. Potentially valuable information from the data in studies
247 that fail to report the events ratio or area under curve (AUC) whilst assessing the prognostic value
248 of fibrinogen will also be missed as the data in these studies will not be included in our data
249 analysis.

250

251 Conclusions

252 Given the prevalence of TBI and the worldwide economic burden, optimising the care of TBI
253 patients is pertinent. If fibrinogen has a prognostic value, it would help healthcare teams practise
254 realistic medicine in accordingly adjusting the goals of care delivered to these patients based on
255 their prognosis. If administering fibrinogen does indeed improve patient outcomes, then this would
256 be an important treatment option for healthcare teams to consider incorporating for TBI patients,
257 especially if fibrinogen administration is protective against haemorrhagic transformation of
258 contusions for example.

259 Therefore, if we find that serum fibrinogen level has prognostic value and that administering
260 fibrinogen improves outcome, this could be important in shared-decision making and in ensuring
261 that patients have improved outcomes.

262

263

264 Declarations

265 Ethics and Study Dissemination

266 No ethical approval is required for this systematic review of already published data. The findings of
267 this paper will be submitted for publishing in a peer-reviewed journal.

268 Authors' contributions

269 Joanne Igoli, Jeremiah Oluwatomi Itodo Daniel, and Temidayo Osunronbi contributed to the
270 conception and design of the study. Joanne Igoli wrote the initial draft of the manuscript and is
271 guarantor of the study. All authors contributed to subsequent versions of the manuscript. All
272 authors read and approved the final manuscript.

273 Acknowledgments

274 We would like to express our gratitude to the Surgery Interest Group of Africa for their support.
275 We would like to thank Idemudia Stephen Ogedegbe for his work on the protocol manuscript, after
276 which his contribution ended.

277

278 References

- 279 1. Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, et al. Estimating the global
280 incidence of traumatic brain injury. *J Neurosurg*. 2018 Apr;130(4):1080–97.
- 281 2. Maas AIR, Menon DK, Manley GT, Abrams M, Åkerlund C, Andelic N, et al. Traumatic brain
282 injury: progress and challenges in prevention, clinical care, and research. *Lancet Neurol*. 2022
283 Nov;21(11):1004–60.
- 284 3. Howe EI, Andelic N, Fure SCR, Røe C, Sørberg HL, Hellstrøm T, et al. Cost-effectiveness
285 analysis of combined cognitive and vocational rehabilitation in patients with mild-to-moderate
286 TBI: results from a randomized controlled trial. *BMC Health Serv Res*. 2022 Dec;22(1):185.
- 287 4. Haarbauer-Krupa J, Pugh MJ, Prager EM, Harmon N, Wolfe J, Yaffe K. Epidemiology of
288 Chronic Effects of Traumatic Brain Injury. *J Neurotrauma*. 2021 Dec 1;38(23):3235–47.
- 289 5. Capizzi A, Woo J, Verduzco-Gutierrez M. Traumatic Brain Injury. *Med Clin North Am*. 2020
290 Mar;104(2):213–38.
- 291 6. Theadom A, Parag V, Dowell T, McPherson K, Starkey N, Barker-Collo S, et al. Persistent
292 problems 1 year after mild traumatic brain injury: a longitudinal population study in New
293 Zealand. *Br J Gen Pract*. 2016 Jan;66(642):e16–23.
- 294 7. Carrick MM, Tyroch AH, Youens CA, Handley T. Subsequent Development of
295 Thrombocytopenia and Coagulopathy in Moderate and Severe Head Injury: Support for Serial
296 Laboratory Examination. *J Trauma Inj Infect Crit Care*. 2005 Apr;58(4):725–30.
- 297 8. Wafaisade A, Lefering R, Tjardes T, Wutzler S, Simanski C, Paffrath T, et al. Acute
298 Coagulopathy in Isolated Blunt Traumatic Brain Injury. *Neurocrit Care*. 2010 Apr;12(2):211–9.
- 299 9. Juratli TA, Zang B, Litz RJ, Sitoci KH, Aschenbrenner U, Gottschlich B, et al. Early Hemorrhagic
300 Progression of Traumatic Brain Contusions: Frequency, Correlation with Coagulation
301 Disorders, and Patient Outcome: A Prospective Study. *J Neurotrauma*. 2014 Sep;31(17):1521–
302 7.
- 303 10. Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoor C, et al. The incidence and
304 magnitude of fibrinolytic activation in trauma patients. *J Thromb Haemost*. 2013
305 Feb;11(2):307–14.
- 306 11. Sikka M, Sodhi R, Kotru M, Singh G. Markers of fibrinolysis in Indian patients with isolated
307 head trauma. *Asian J Neurosurg*. 2019 Mar;14(01):118–21.
- 308 12. Lv K, Yuan Q, Fu P, Wu G, Wu X, Du Z, et al. Impact of fibrinogen level on the prognosis of
309 patients with traumatic brain injury: a single-center analysis of 2570 patients. *World J Emerg*
310 *Surg*. 2020 Dec;15(1):54.
- 311 13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
312 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar
313 29;n71.
- 314 14. Mandrekar JN. Receiver Operating Characteristic Curve in Diagnostic Test Assessment. *J*
315 *Thorac Oncol*. 2010 Sep;5(9):1315–6.
- 316 15. Shim SR, Lee J. Dose-response meta-analysis: application and practice using the R software.
317 *Epidemiol Health*. 2019 Mar 28;41:e2019006.
- 318 16. Grooten WJA, Tseli E, Ång BO, Boersma K, Stålnacke BM, Gerdle B, et al. Elaborating on the
319 assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS—
320 aspects of interrater agreement. *Diagn Progn Res*. 2019 Dec;3(1):5.
- 321 17. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane
322 Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011 Oct
323 18;343(oct18 2):d5928–d5928.

- 324 18. Sterne J, Hernán M, McAleenan A, Reeves B, Higgins J. Chapter 25: Assessing risk of bias in a
325 non-randomized study. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al.,
326 editors. *Cochrane Handbook for Systematic Reviews of Interventions* [Internet]. Version 6.4.
327 2023 [cited 2024 May 1]. Available from:
328 <https://training.cochrane.org/handbook/current/chapter-25>
- 329 19. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging
330 the quality of evidence in reviews of prognostic factor research: adapting the GRADE
331 framework. *Syst Rev*. 2013 Dec;2(1):71.
- 332 20. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1.
333 Introduction—GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol*.
334 2011 Apr;64(4):383–94.
- 335 21. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al.
336 Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. *BMJ*.
337 2020 Jan 16;l6890.